Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Thea Pharma, Inc.

US Class II Ongoing · initiated 2026-04-23

Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.

Thea Pharma, Inc.

US Class II Ongoing · initiated 2026-04-23

Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.

JB Chemicals and Pharmaceuticals Ltd

US Class II Ongoing · initiated 2026-04-23

Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-04-22

Lack of assurance of Sterility: potential product contamination

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-04-22

Lack of assurance of Sterility: potential product contamination

Alcon Research LLC

US Class II Ongoing · initiated 2026-04-21

Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.

Alcon Research LLC

US Class II Ongoing · initiated 2026-04-21

Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2026-04-21

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

SCOPE HEALTH

US Class II Ongoing · initiated 2026-04-20

Lack of Assurance of Sterility

Acella Pharmaceuticals, LLC

US Class II Ongoing · initiated 2026-04-20

Chemical contamination; presence of lead and lithium above specification

Max Slim Alpha-GPC + Citicoline

Canada Type II Ongoing · initiated 2026-04-20

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

SUVEXX

Canada Type III Ongoing · initiated 2026-04-20

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

Harrow Eye LLC

US Class II Ongoing · initiated 2026-04-17

Lack of Assurance of Sterility

American Regent, Inc.

US Class III Ongoing · initiated 2026-04-16

Labeling: Missing Label

Nitrous Oxide Chargers

Canada Type I Ongoing · initiated 2026-04-15

Product safety. Do not inhale nitrous oxide products for recreational purposes.Seek immediate medical attention from a health care professional (physician, nurs…

Premier Dental Products Co

US Class III Ongoing · initiated 2026-04-14

Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (2027-09-14). …

Nitrous Oxide Charger

Canada Type I Ongoing · initiated 2026-04-14

Product safety. Do not inhale nitrous oxide products for recreational purposes.Seek immediate medical attention from a health care professional (physician, nurs…

Unichem Pharmaceuticals USA Inc.

US Class III Ongoing · initiated 2026-04-13

Subpotent drug

Apo-Fluoxetine

Canada Type III Ongoing · initiated 2026-04-10

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

The Harvard Drug Group LLC

US Class II Ongoing · initiated 2026-04-09

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

Apotex Corp.

US Class II Ongoing · initiated 2026-04-08

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Blaine Labs Inc

US Class II Ongoing · initiated 2026-04-08

CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

Blaine Labs Inc

US Class II Ongoing · initiated 2026-04-08

CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

Blaine Labs Inc

US Class I Ongoing · initiated 2026-04-08

Microbial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus spp

Blaine Labs Inc

US Class II Ongoing · initiated 2026-04-08

CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry